TY - JOUR
T1 - A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients
T2 - Background and methodology of the MONITOR-CKD5 study
AU - Gesualdo, Loreto
AU - London, Gérard
AU - Turner, Matthew
AU - Lee, Christopher
AU - MacDonald, Karen
AU - Goldsmith, David
AU - Covic, Adrian
AU - Zaoui, Philippe
AU - Combe, Christian
AU - Mann, Johannes
AU - Dellanna, Frank
AU - Muenzberg, Michael
AU - Abraham, Ivo
N1 - Funding Information:
Acknowledgments The study is sponsored by research grants from Sandoz Biopharmaceuticals, a Novartis company, Holzkirchen, Germany. The authors thank Liam Smith for editorial, proofreading, and administrative assistance. Data will be analysed independently from the Sponsor, although the Sponsor will have the right of review and comment.
PY - 2013/8
Y1 - 2013/8
N2 - Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.
AB - Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.
KW - Biosimilar
KW - Erythropoietin
KW - Haemodialysis
KW - Pharmacoepidemiology
KW - Renal anaemia
UR - http://www.scopus.com/inward/record.url?scp=84880421358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880421358&partnerID=8YFLogxK
U2 - 10.1007/s11739-011-0622-7
DO - 10.1007/s11739-011-0622-7
M3 - Article
C2 - 21590439
AN - SCOPUS:84880421358
SN - 1828-0447
VL - 8
SP - 389
EP - 399
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
IS - 5
ER -